4.5 Article

The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction

期刊

EUROPEAN JOURNAL OF HEART FAILURE
卷 14, 期 6, 页码 605-612

出版社

OXFORD UNIV PRESS
DOI: 10.1093/eurjhf/hfs029

关键词

Heart failure; Risk model; Risk score; Worsening heart failure

资金

  1. NovaCardia, a subsidiary of Merck
  2. Merck
  3. Abbott
  4. Amgen
  5. Biogen Idec
  6. Corthera
  7. Cytokinetics
  8. Johnson and Johnson
  9. Scios
  10. Novartis
  11. Relypsa
  12. Solvay
  13. NovaCardia
  14. National Institute for Health Research [NF-SI-0611-10227] Funding Source: researchfish

向作者/读者索取更多资源

In patients with acute heart failure (AHF), early worsening heart failure (WHF) predicts a significant proportion of post-discharge readmissions and mortality. We aimed to identify the predictors of 7-day heart failure events or death in patients hospitalized with AHF. A predictive model and risk score for the short-term primary composite endpoint of 7-day death, HF rehospitalization, or WHF was created using variables collected within 24 h of admission from patients with complete data (n 2015) enrolled in the PROTECT trial of AHF patients. The 7-day composite was experienced by 294 patients (14.6), with a mortality rate of 1.8 (n 37), HF rehospitalization rate of 0.5 (n 9), and WHF rate of 13.1 (n 264). In multivariable analyses, the strongest predictor of short-term morbidity and mortality was higher blood urea nitrogen (BUN) concentration. Additional independent predictors of a worse outcome were lower serum albumin, cholesterol, and systolic blood pressure, as well as higher heart rate and respiratory rate. Model coefficients were converted to an additive risk score for predicting the 7-day composite endpoint with a total point range of 0100. The risk score allowed discrimination of a wide spectrum of risk (4.8 risk with score 35, to 28.7 risk with score 55). Using the PROTECT 7-day risk model and score, the main determinants of an adverse outcome for AHF patients included impaired metabolic status, neurohormonal activation, and reduced cardiac performance, gauged by BUN, serum albumin and cholesterol levels, systolic blood pressure, heart rate, and respiratory rate.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据